Glioblastoma Market: Epidemiology, Treatment Landscape, and Key Players | DelveInsight, Prominent companies active in this space include Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest

As per DelveInsight, the Glioblastoma Market is expected to expand at a healthy growth rate during the forecast period (2024-2034), owing to the launch of new therapies in the market and the rise in the number of cases.

Emerging therapies such as Avastin, Temodar/Temodal, ITI-1000 (pp65 DC Vaccine), VBI-1901, Selinexor (KPT-330), Trans Sodium Crocetinate, Ofranergene obadenovec (VB-111), and others are anticipated to drive growth in the Glioblastoma market over the coming years.

DelveInsight has introduced a new report, "Glioblastoma - Market Insights, Epidemiology, and Market Forecast 2034", which provides a comprehensive overview of the disease, covering historical and projected epidemiology along with market trends across the United States, EU5 (Germany, Spain, Italy, France, and the UK), and Japan.

Discover about the Glioblastoma market report @ https://www.delveinsight.com/report-store/glioblastoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Some of the key facts of the Glioblastoma Market Report:

*
According to DelveInsight, the glioblastoma market is expected to experience substantial growth from 2024 to 2034, fueled by the launch of new therapies and a rising number of diagnosed cases.

*
In the United States, gender-specific incidence data from 2021 showed a higher prevalence among males, with about 7,705 cases, compared to a smaller number in females.

*
In December 2024, Kazia Therapeutics received feedback from the FDA indicating that its brain cancer drug paxalisib is unlikely to gain accelerated approval, as the 3.8-month overall survival benefit observed in the Phase II/III GBM-AGILE trial did not meet the required threshold. Conversely, on October 15, 2024, the FDA granted Fast Track designation to Lantern Pharma's LP-184, a small-molecule alkylating agent for glioblastoma. LP-184 induces DNA damage to destroy tumor cells and is being evaluated in a Phase 1a trial for multiple solid tumors, including GBM. The designation is intended to expedite its development and review, reflecting the urgent need for effective treatments against aggressive brain cancers.

*
Leading players in the glioblastoma space include Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai, Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, TME Pharma, and others.

*
Promising emerging therapies include Dazukibart (PF-06823859) and additional candidates currently in development.

Glioblastoma Overview

Glioblastoma is the most prevalent primary tumor of the central nervous system (CNS), especially among adults. While advances in diagnostic methods and therapeutic approaches have been made, the overall prognosis for patients remains unfavorable. These tumors most often develop in the cerebrum, the region of the forebrain responsible for higher functions such as speech and emotional processing. The precise cause of glioblastoma is still uncertain. In some cases, it develops from the malignant progression of pre-existing low-grade astrocytomas, while in others, it arises spontaneously (de novo) without any prior tumor.

Glioblastoma Market Outlook

Treating glioblastoma is especially challenging because tumor cells can respond differently to therapies-some are sensitive, while others show resistance. Consequently, management often relies on a multimodal strategy, typically combining surgery, chemotherapy, radiation therapy, or stereotactic radiosurgery. Post-surgical treatments, such as radiation or chemotherapy, are frequently employed to improve patient outcomes.

Surgery is usually the first-line intervention, serving to confirm the diagnosis, relieve intracranial pressure, and remove as much of the tumor as safely possible. This method, known as "maximum safe resection," focuses on excising the tumor while minimizing the risk of permanent neurological damage.

The glioblastoma treatment landscape is evolving with innovative therapies, including gene therapy candidates like Ofranergene obadenovec (VB-111) from VBL Therapeutics, as well as immunotherapy and vaccine-based approaches such as VBI-1901, AV-Glioblastoma-1, ITI-1000 (pp65 DC Vaccine), and Tasadenoturev (DNX-2401), being advanced by companies like VBI Vaccines, Aivita Biomedical, Immunomic Therapeutics, and DNAtrix.

The pipeline features several promising therapies in mid-to-late clinical stages. Notable contenders include Paxalisib (GDC-0084) from Kazia Therapeutics, LAM561 from Laminar Pharmaceuticals, and Tasadenoturev (DNX-2401) from DNAtrix, all anticipated to significantly shape the market outlook in the coming years.

Discover how the Glioblastoma market is rising in the coming years @ https://www.delveinsight.com/sample-request/glioblastoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Glioblastoma Emerging Drugs:

*
Ofranergene obadenovec (VB-111): VBL Therapeutics

*
Trans Sodium Crocetinate: Diffusion Pharmaceuticals

*
Selinexor (KPT-330): Karyopharm Therapeutics

*
VBI-1901: VBI Vaccines

*
ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics

Glioblastoma Marketed Drugs

*
Avastin: Genentech

*
Temodar/Temodal: Merck

Scope of the Glioblastoma Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Glioblastoma Companies: Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai and Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, TME Pharma, and others

*
Key Glioblastoma Therapies: Avastin, Temodar/Temodal, ITI-1000 (pp65 DC Vaccine), VBI-1901, Selinexor (KPT-330), Trans Sodium Crocetinate, Ofranergene obadenovec (VB-111), and others

*
Glioblastoma Therapeutic Assessment: Glioblastoma current marketed and Glioblastoma emerging therapies

*
Glioblastoma Market Dynamics: Glioblastoma market drivers and Glioblastoma market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Glioblastoma Unmet Needs, KOL's views, Analyst's views, Glioblastoma Market Access and Reimbursement

To know what's more in our Glioblastoma report, visit https://www.delveinsight.com/report-store/glioblastoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Key benefits of the Glioblastoma Market Report:

*
Glioblastoma market report covers a descriptive overview and comprehensive insight of the Glioblastoma Epidemiology and Glioblastoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).

*
The Glioblastoma market report provides insights into the current and emerging therapies.

*
The Glioblastoma market report provides a global historical and forecasted market covering drug outreach in 7MM.

*
The Glioblastoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Glioblastoma market.

Got queries? Click here to know more about the Glioblastoma market Landscape [https://www.delveinsight.com/sample-request/glioblastoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Glioblastoma Patient Share (%) Overview at a Glance

5. Glioblastoma Market Overview at a Glance

6. Glioblastoma Disease Background and Overview

7. Glioblastoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Glioblastoma

9. Glioblastoma Current Treatment and Medical Practices

10. Unmet Needs

11. Glioblastoma Emerging Therapies

12. Glioblastoma Market Outlook

13. Country-Wise Glioblastoma Market Analysis (2020-2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Glioblastoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Glioblastoma Market Outlook 2034 [https://www.delveinsight.com/report-store/glioblastoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Related Reports:

Glioblastoma Pipeline Insights, DelveInsight

"Glioblastoma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Glioblastoma market. A detailed picture of the Glioblastoma pipeline landscape is provided, which includes the disease overview and Glioblastoma treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=glioblastoma-market-epidemiology-treatment-landscape-and-key-players-delveinsight-prominent-companies-active-in-this-space-include-bayer-chimerix-aivita-biomedical-denovo-biopharma-northwest]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.